SCHEMBL2919342

SCHEMBL2919342

O=P(O)(O)OC[C@H]1O[C@@H](n2cnc3c2=NCN2C=CNC=32)[C@H](O)[C@@H]1O

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ATIC P31939 3/20 0.49
FBP1 P09467 2/20 0.49
IMPDH2 P12268 6/20 0.48
IMPDH1 P20839 2/20 0.48
GART P22102 1/20 0.48
TAS1R3 Q7RTX0 5/20 0.48
TAS1R1 Q7RTX1 5/20 0.48
DNPH1 O43598 3/20 0.48
PRKAB2 O43741 1/20 0.48
TRPM2 O94759 1/20 0.48
LDHA P00338 1/20 0.48
ADRB2 P07550 1/20 0.48
SRC P12931 1/20 0.48
ADORA1 P30542 1/20 0.48
P2RY2 P41231 1/20 0.48
P2RY1 P47900 1/20 0.48
PRKAG1 P54619 1/20 0.48
PRKAA2 P54646 1/20 0.48
PDE4D Q08499 1/20 0.48
KCNH2 Q12809 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5721746 0.92 P2RX3 (0.52) SRCP2RY2P2RY1SMN1; SMN2P2RY11
SCHEMBL11884609 0.87 P2RY2 (0.45) ATICFBP1IMPDH2IMPDH1P2RY2
SCHEMBL1429148 0.85 ADA (0.46) ATICADORA1SMN1; SMN2
Hydrochloric Acid SCHEMBL5928106 0.84 ADA (0.45) ATICADORA1SMN1; SMN2
SCHEMBL9549302 0.82 ATIC (0.49) ATICFBP1IMPDH2IMPDH1GART
SCHEMBL11884671 0.81 ADA (0.34) ATICADORA1SMN1; SMN2
SCHEMBL19458230 0.79 POLB (0.45) P2RY2P2RY1
SCHEMBL264616 0.79 ATIC (0.52) ATICFBP1IMPDH2IMPDH1GART
SCHEMBL6704190 0.79 ATIC (0.57) ATICFBP1GARTTAS1R3TAS1R1
SCHEMBL8840654 0.79 ATIC (0.52) ATICFBP1IMPDH2IMPDH1GART

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0232967-B1 COMPETITIVE HOMOGENEOUS ASSAY AMOCO CORPORATION (US) 1993-04-28 EP claimed
EP-0232967-A2 Competitive homogeneous Assay AMOCO CORPORATION (US) 1987-08-19 EP claimed
US-20240165209-A1 PLACENTAL ALKALINE PHOSPHATASE FOR REDUCING THE LOSS OF RED BLOOD CELLS, WHITE BLOOD CELLS, AND PLATELETS IN CHEMOTHERAPY TREATED CANCER PATIENTS ZOLTAN LABORATORIES LLC (US) 2024-05-23 US disclosed
WO-2022150034-A1 PLACENTAL ALKALINE PHOSPHATASE FOR STARTING EARLY TREATMENT OF CANCER PATIENTS EXHIBITING NO DETECTABLE LOSS OF BODY AND MUSCLE WEIGHT AS YET TO PREVENT OR REDUCE THE LOSS OF MUSCLE PROTEINS ZOLTAN LABORATORIES, LLC (US) 2022-07-14 WO disclosed
EP-2043677-B1 COMBINATIONS OF HUMAN PROTEINS TO ENHANCE VIABILITY OF STEM CELLS AND PROGENITOR CELLS ZOLTAN LABORATORIES LLC (US) 2018-06-13 EP disclosed
EP-1965830-B1 USE OF ALKALINE PHOSPHATASE TO MAINTAIN HEALTHY TISSUE MASS IN MAMMALS ZOLTAN LAB LLC (US) 2014-05-14 EP disclosed
EP-1919502-B1 PROTEIN COMPOSITIONS FOR PROMOTING WOUND HEALING AND SKIN REGENERATION ESSENTIAL SKINCARE LLC (US) 2013-09-11 EP disclosed
EP-1572230-B1 PLACENTAL ALKALINE PHOSPHATASE TO CONTROL DIABETES ZOLTAN LAB (US) 2010-09-08 EP disclosed
EP-1733734-A2 Placental alkaline phosphatase to control diabetes Zoltan Laboratories (US) 2006-12-20 EP disclosed